Drawing for MEDIDELIC

USPTO serial 90506292

MEDIDELIC

Reviewed by CopyMark Law Group

Reg. 7299931Status 700Registered
Filing date
Status date
Registration date
Feb 6, 2024
Examiner
SULLIVAN, JOHN C
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MEDIDELIC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Dean H. Kayes

Dean H. Kayes LAW OFFICE OF DEAN H. KAYES, P.C.1028 N. LAKE AVE. SUITE 202PASADENA, CA 91104UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
042Biotechnology research; Research and development in the pharmaceutical, bioenergetic imprinting and biotechnology fields; Providing information on the subject of scientific research in the field of biochemistry, biological signaling and biotechnology; Development of new technology for others in the field of biotechnology; Scientific Research and Development of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) modeling, physiologically based pharmacokinetic (PBPK) and physiologically based biopharmaceutics (PBBM) modeling and simulation software for the pharmaceutical and biotechnology industries; Research and Development of software that allows pharmaceutical scientists to predict certain key potential endpoints and dynamics, in silico, thereby reducing research and development costs and helping clients make better projects decisions sooner that includes PBBK (Physical based pharmacokinetics), PBBM (Physiologically based biopharmaceutics), NOAEL (No observed adverse effect level); Scientific Research and Development utilizing a proprietary algorithm and artificial intelligence that utilizes a combination of lifestyle, hospitalization, emergency room use, mortality and outcomes data to assist the healthcare industry and workers in identifying groups at high risk and populations that can benefit from various therapeutic approaches; Scientific Research and Development of drugs and therapies through applying interactive maps that identify ideal target populations for various therapeutic approaches including the mapping of surfaces that apply socio, economic and environmental factors such as access to or lack of access to transportation or nutritious food, or exposure to high stress and artificial intelligence analysis considering the suitability of various drugs or therapiesACTIVENov 28, 2022

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 6, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 6, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 3, 2024SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 2, 2024FIXDELECTRONIC RECORD REVIEW COMPLETE
Dec 22, 2023ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Dec 20, 2023SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Dec 19, 2023CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Dec 19, 2023XAECEXAMINER'S AMENDMENT ENTERED
Dec 19, 2023GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 19, 2023GNEAEXAMINERS AMENDMENT E-MAILED
Dec 19, 2023SNEASU-EXAMINER'S AMENDMENT WRITTEN
Sep 4, 2023GNFNNOTIFICATION OF FINAL REFUSAL EMAILED
Sep 4, 2023GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 4, 2023CNFRSU - FINAL REFUSAL - WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 31, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Aug 31, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 31, 2023ALIEASSIGNED TO LIE
Apr 19, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 20, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 20, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 20, 2023CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 20, 2023SUPCSTATEMENT OF USE PROCESSING COMPLETE
Jan 10, 2023IUAFUSE AMENDMENT FILED
Jan 10, 2023EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Dec 1, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 30, 2022EX1GSOU EXTENSION 1 GRANTED
Nov 29, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 24, 2022NREVNOTICE OF REVIVAL - E-MAILED
Oct 22, 2022TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION
Oct 22, 2022PETGPETITION TO REVIVE-GRANTED
Oct 22, 2022PROATEAS PETITION TO REVIVE RECEIVED
Sep 6, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 5, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 1, 2022EXT1SOU EXTENSION 1 FILED
Feb 1, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 7, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 7, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 17, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 2, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Nov 2, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Nov 2, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 2, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 24, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 24, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 24, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 20, 2021DOCKASSIGNED TO EXAMINER
May 6, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 6, 2021NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance